Skip to Main Content

Paper Details

Safety and efficacy of CRISPR-based non-viral <i>PD1</i> locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I study.
EClinicalMedicine
9
2023
Author NameAffiliation
Mingyao LiuInstitute of Biomedical Sciences and School of Life Sciences, East China Normal University
Mingyao LiuBRL Medicine Inc.
  • 1 - 2

Datasets

Release 1.2